-+ 0.00%
-+ 0.00%
-+ 0.00%

Leads Biolabs submits China NDA for opamtistomig in advanced EP-NEC

PUBT·09/21/2026 16:34:28
Listen to the news
Leads Biolabs submits China NDA for opamtistomig in advanced EP-NEC
  • Leads Biolabs filed an NDA with China’s NMPA for opamtistomig (LBL-024) in advanced extrapulmonary neuroendocrine carcinoma.
  • The filing is backed by results from a registrational Phase IIb monotherapy study in patients who had received at least two prior systemic regimens.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609211046PRIMZONEFULLFEED9830569) on September 21, 2026, and is solely responsible for the information contained therein.